Susceptibility of 302 methicillin-resistant Staphylococcus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 18, Issue 7, 1999, Pages 528-530

  Schmitz, F J ^a   Krey, A ^a   Geisel, R ^a   Verhoef, J ^b   Heinz, H P ^a   Fluit, A C ^b   Mittermayer, H ^b   Struelens, M ^b   Acar, J ^b   Jarlier, V ^b   Etienne, J ^b   Courcol, R ^b   Daschner, F ^b   Hadding, U ^b   Legakis, N ^b   Schito, G C ^b   Mancini, C ^b   Heczko, P ^b   Hyrniewicz, W ^b   Costa, D ^b   Perea, E ^b   Baquero, F ^b   Alvarez, R M ^b   Bille, J ^b   French, G ^b   more..

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; FOSFOMYCIN; FUSIDIC ACID; GENTAMICIN; METICILLIN; OXAZOLIDINONE DERIVATIVE; PSEUDOMONIC ACID; RIFAMPICIN; STREPTOGRAMIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE; EUROPE; HOSPITALS, UNIVERSITY; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0032753003     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050340     Document Type: Article

References (15)

1. 1. Chambers HF: Parenteral antibiotics for the treatment of bacteremia and other serious staphylococcal infections. In: Crossley KB, Archer GL (eds): The staphylococci in human disease. Churchill Livingstone, New York (1997) pp 583-601
2. 2. Schmitz FJ, Jones ME: Antibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices? International Journal of Antimicrobial Agents (1997) 9:1-19
3. 3. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I: Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet (1997) 350:1670-1673
4. 4. Furamatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy (1997) 40:135-136
5. 5. Hanaki H, Kuwahara A, Bovle-Vavra S, Daum RS, Labischinsky H, Hiramatsu K: Activated cell wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. Journal of Antimicrobial Chemotherapy (1998) 42:199-209
6. 6. Centers for Disease Control and Prevention: Update: Staphylococcus aureus with reduced susceptibility to vancomycin in the United States (1997). Morbidity and Mortality Weekly Report (1997) 46:2064-2068
7. 7. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial tests for bacteria that grow aerobically. Approved standard M7-A4. NCCLS, Wayne, PA (1997)
8. 8. Schmitz FJ, Verhoef J, Fluit AC, and the SENTRY Participants Group: Prevalence of aminoglycoside resistance in 20 European university hospitals participating in the European SENTRY surveillance program. European Journal of Clinical Microbiology & Infectious Diseases (1999) 18:414-421
9. 9. Schmitz FJ, MacKenzie CR, Hofmann B, Verhoef J, Finken-Eigen M, Heinz HP, Köhrer K: Specific information concerning taxonomy, pathogenicity, and methicillin-resistance of staphylococci obtained by a multiplex-PCR. Journal of Medical Microbiology (1997) 46:773-778
10. 10. Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, O'Hara CM, Clark NC, Hiramatsu K: Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. Journal of Clinical Microbiology (1998) 36:1020-1027
11. 11. Wiedemann B: Empfindlichkeitsprüfung von Bakterien. In: Burkhard F (ed): Mikrobiologische Diagnostik. Thieme, Stuttgart (1992) pp 714-733
12. 12. Finlay JE, Miller LA, Poupard JA: Interpretative criteria for testing susceptibility of staphylococci to mupirocin. Antimicrobial Agents and Chemotherapy (1997) 41:1137-1139
13. 13. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I: Methicillin-resistant Staphylococcus aureus in Europe. European Journal of Clinical Microbiology & Infectious Diseases (1994) 13:50-55
14. 14. Aldrige KE, Schiro DD, Varner LM: In-vitro anti-staphylococcal activity and testing of RP 59500, a new streptogramin, by two methods. Antimicrobial Agents and Chemotherapy (1992) 36:854-855
15. 15. Kaatz GW, Seo SM: In-vitro activities of oxazolidinone compounds U 100592 and U 100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrobial Agents and Chemotherapy (1996) 40:799-801